immunotherapy

1:59
Multiple myeloma musings: highlights from 2018 data
Joshua Richter
04:11
An exciting era for CAR T-cell therapy
Mohamad Mohty
03:22
JCAR017 for relapsed/refractory CLL
Tanya Siddiqi
2:42
Tislelizumab for R/R classical Hodgkin lymphoma
Yuqin Song
2:49
The CAR-T tsunami: an overview & brief history
Michel Sadelain
4:17
Intestinal microbiota may unlock the true potential of HCT
Jonathan Peled
1:14
Off-the-shelf CAR T-cell therapy
Dietmar Berger
2:20
Telomere length can predict the outcome of FCR chemoimmunotherapy in CLL
Christopher Fegan
2:19
AMG 420 BiTE for R/R multiple myeloma
Thierry Facon
2:23
The MAIA study and other myeloma highlights from ASH 2018
Gareth Morgan
0:55
CAR-T and ibrutinib in combination: a promising treatment for CLL
Lydia Scarfò
4:04
bb21217 results: a next-generation anti-BCMA CAR-T for R/R MM
Nina Shah
2:53
Early look at data for CAR-T bb21217 in R/R MM
Noopur Raje
1:29
CAR T-cell updates in CLL
William Wierda
2:28
Predictors of expansion/response to anti-BCMA CAR T-cells in R/R multiple myeloma
Adam Cohen
2:25
PD-1 blockade as salvage following anti-BCMA CAR-T in R/R myeloma
Adam Cohen
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

VJHO needs the contact information you provide to inform you about our latest hemonc news and videos, educational courses and industry supported content (some of which may be promotional in nature). You may unsubscribe from these communications at anytime. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy.

The content of VJHemOnc is intended for healthcare professionals